Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
Sponsor: University of Texas Southwestern Medical Center
Summary
The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or Pio+WL. Participants will be evaluated at baseline and after 24 weeks of intervention while on a fixed metabolic diet to exclude the confounding effects of diet and perspiration. The primary endpoint will be change in upH, and multiple additional endpoints (serum, urine, imaging) will be assessed.
Key Details
Gender
All
Age Range
21 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2019-10-17
Completion Date
2025-05-28
Last Updated
2026-08-31
Healthy Volunteers
No
Conditions
Interventions
Pioglitazone 45 mg
45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
Weight Loss
Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
Pioglitazone + Weight Loss
Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
Locations (1)
University of Texas Southwestern Medical Center
Dallas, Texas, United States